- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04541459
Validation of New Devices Against Ambient Electromagnetic Radiation
Validation of New Devices Against Ambient Electromagnetic Radiation: A Randomized Double Blind Controlled Study
Project Summary Cell phones have become indispensable devices in the investigator's daily life. These phones operate between 400 and 2000 MHz frequency bands and emit radiofrequency electromagnetic waves (EMW). Radio-frequency electro-magnetic field exposure from cell phones or other sources of microwaves have deleterious effects on sperm parameters (like sperm count, morphology, motility). Further, EMW radiation emitted by mobile phones affects cells and organelles, and results in disorientation of charged molecules within the cytosol and a distortion of electron flow along the internal membranes of the cells. These cellular changes results in the generation of ROS leading to oxidative stress, which in turn results in radiation-induced sperm DNA fragmentation.
Radiation shield can help provide protection from high levels of EMW radiations deflecting, diverting, and absorbing the radiation between the user and the source. A new EMW radiation shield, Qi-Shield device developed by Waveguard GmbH (Bautzen, Germany) provides protection against the radiations emitted by the smartphone and laptop devices. Qi-Shield utilizes conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
Study Aims:
To evaluate the changes in the semen parameters from the use of Qi-Shield device in sham (control) and user groups To determine the molecular changes pertaining to sperm proteins from the use of Qi-Shield device in sham (control) and user groups
Significance The negative health consequences of EMWs have been documented across a wide range of device types, exposure frequencies and doses (Giuliani, 2010), at field strengths substantially below the International Commission on Non-Ionizing Radiation Protection (ICNIRP) guidelines for permissible exposures. In the absence of a revision in the ICNIRP guidelines, near-term public exposures to EMWs will most certainly continue to increase, despite the scientific evidence suggesting more careful review and recommendations to limit exposure to electromagnetic fields as much as possible. At present, there is no veritable means for counteracting the negative health consequences of human-made EMWs, revealing an unmet need for a means of protecting from or ameliorating the negative effects of EMWs, and the need for devising strategies for creating safer living and working environments in a time of increasing EMW exposures.
Positive results in this study would demonstrate a means of counteracting negative effects on human sperm due to EMWs. Documentation of protection due to the Qi-Shield devices would show proof of principle that a low-cost passive device, portable and without battery or mains power, can provide improvements in human sperm parameters, with promise for a means of counteracting EMW-reduced fertility in large numbers of people. Confirmation of changes on protein expression would provide data needed to identify specific pathways of action, insight that is necessary for a more detailed understanding of the mechanisms of action of the EMW protection effect. Taken together, these results would suggest further lines of study in EMW protection, and provide clinical support for the adoption of EMW-protecting devices in the home and workplace.
Study Overview
Status
Conditions
Detailed Description
Normal healthy men enrolled in the study will be asked to provide semen specimens prior to the use of device. Samples will be produced with a minimum of 48-72 hours of abstinence. Further, the subjects will be blindly assigned with either sham Qi-Shield or Qi-Shield device and will be instructed to use the device for a duration of 8 weeks .Semen samples will be provided by the subjects at 0, 4 and 8 weeks interval.
Group 1 study subjects will be provided with sham Qi-Shield device, whereas Group 2 study subjects with be provided with actual Qi-Shield device. Each user will be provided with a small carrier bag to accommodate the device during their travel. The participants are advised to keep the device within 3 meters of range as per the manufacturer instructions for a duration of 8 weeks.
Semen analysis All specimens will be collected by masturbation at the Andrology Laboratory after 48-72 hours of sexual abstinence. Samples will be allowed to liquefy completely for 15-20 minutes at 37C before further processing. After complete liquefaction, semen analysis will be carried out using automated LensHooke™X1 PRO semen quality analyzer (Bonraybio Co., Ltd) to determine sperm concentration and motility, progressive motility (Agarwal et al., 2019). Viability will be determined by Eosin-Nigrosin stain if motility is <25%. Smears of the raw semen will be stained with a Diff-Quik kit (Baxter Healthcare Corporation, Inc., McGaw Park, IL) for assessment of sperm morphology according to strict criteria as described in the WHO, 5th edition guideline.
White blood cell measurement When the round cell concentration in the ejaculate is >1 X million/mL or >5 round cells per high power field, the sample will be tested for leukocytospermia, i.e. >1 X million white blood cells/mL. This will be confirmed by the peroxidase or the Endtz test.
Measurement of Oxidation Reduction Potential ORP measures the transfer of electrons from a reductant (or antioxidant) to an oxidant. ORP is measured in millivolts (mV). In the current study, ORP will be measured using novel galvanostat-based technology-the MiOXSYS System (Aytu Bioscience, Englewood, CO). Briefly, 30µL of liquefied semen will be loaded on the MiOXSYS sensor. The sensor will be inserted into the MiOXSYS analyzer. Static ORP (sORP), measured in mV, is the integrated measure of the existing balance between total oxidants and reductants in a biological system. Data will be normalized with sperm concentration. ORP will be expressed as mV/ million sperm/mL.
DNA fragmentation DNA fragmentation will be assessed via Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay (TUNEL assay). Briefly, 2 million spermatozoa will be washed in phosphate buffered saline (PBS) and resuspended in 3.7% paraformaldehyde. A total of 2 aliquots (A and B) will be used for each donor, one for ORP measurement and other for measurement of sperm DNA fragmentation. These will be placed on ice for 30-60 minutes at 4C. Thereafter, the spermatozoa will again be washed to remove the paraformaldehyde and then re-suspended in 70% ice-cold ethanol, stored at -20C until the time of analysis.
Sperm DNA fragmentation will be evaluated using a TUNEL assay with an Apo-DirectTM kit (Pharmingen, San Diego, CA). Positive and negative kit controls provided by the manufacturer and positive test prepared by treating with hydrogen peroxide controls will be included for each run. Following a second wash in PBS to remove ethanol, the sperm pellets are re-suspended in 50 µL of freshly prepared staining solution for 60 minutes at 37C. The staining solution contains terminal deoxytransferase (TdT) enzyme, TdT reaction buffer, fluorescein isothiocynate tagged deoxyuridine triphosphate nucleotides (FITC-dUTP) and distilled water. All specimens are further washed in rinse buffer and re-suspended in 0.5 mL of propidium Iodide/RNase solution, and incubated for 30 minutes followed by flow cytometric analysis.
BD C6 Acuri cytometry analysis: All fluorescence signals of labelled spermatozoa will be analyzed by the flow cytometer BD Accuri Flow cytometer (Becton Dickinson, San Jose, CA). About 10,000 spermatozoa will be examined for each assay at a slow flow rate of <100 cells/sec. The laser excitation is provided at 2 wavelengths of 488 nm supplied by a solid blue state laser at 20mW and 640 nm powered by 14.7mW diode red laser. Green fluorescence (480-530 nm) is measured in the FL-1 channel and red fluorescence (640 nm) in the FL-2 channel. The percentage of positive cells (TUNEL-positive) will be calculated using the flow cytometer software.
Proteomic analysis Individual samples collected from each group will be subjected to 65% percoll gradient to specifically remove the white blood cells. Semen samples will be washed with PBS three times. Once the supernatant is removed, spermatozoa will be solubilized in radio-immunoprecipitation assay (RIPA) lysis buffer containing the proteinase inhibitor cocktail. After complete lysis of the spermatozoa, protein concentration will be determined using a bicinchoninic acid (BCA) kit and equal amounts of proteins will be fractionated using SDS-Page 1D gel electrophoresis. Separated bands will be cut from a single Coomassie blue stained 1D gel and analyzed. The bands will be washed, reduced, alkylated, and digested with trypsin. The digests will be separated by capillary column LC-tandem MS and the CID spectra searched against the human reference sequence database.
Functional annotation and enrichment analysis will be performed using publicly available bioinformatics annotation tools and databases such as GO Term Finder, GO Term Mapper, UniProt, Software Tools for Researching Annotations of Proteins (STRAP), Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.niaid.nih.gov), and proprietary software package such as IPA (Ingenuity Pathway Analysis) from Ingenuity® Systems, used to obtain consensus-based, comprehensive functional context for the large list of proteins derived from proteomic study. The data will be subjected to STRING (Search Tool for the Retrieval of Interacting Genes/Proteins), a biological database and web resource of known and predicted protein-protein interactions. This will help in identifying critical proteins involved in reproductive function.
Data analysis All the data will be analyzed using the using the MedCalc Software (V. 17.8; MedCalc Software, Ostend, Belgium). Paired t-test will be used if the distribution is normal. Whereas, Wilcoxon signed rank tests will be used for parameters that do not follow normal distribution. For paired T-test comparisons based on 20 samples for each experiment, the power should be least 90% for parameters where a coefficient of variation is no more than 20%.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Ashok Agarwal, PhD
- Phone Number: +1(216) 444-9485
- Email: agarwaa@ccf.org
Study Contact Backup
- Name: Manesh K Panner Selvam, PhD
- Phone Number: +1(216) 414-9207
- Email: pannerm@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- American Center for Reproductive Medicine, Cleveland Clinic
-
Contact:
- Ashok Agarwal, PhD
- Phone Number: 216-444-9485
- Email: agarwaa@ccf.org
-
Principal Investigator:
- Ashok Agarwal, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Normal healthy men with normozoospermic semen parameters.
Exclusion Criteria:
- Subjects with a history of smoking
- Chewing tobacco
- Alcohol consumption
- Antioxidant supplementation
- Orchitis, varicocele, tuberculosis, diabetes mellitus, and hypertension
- Viral/bacterial infection in the past 4 weeks
- History of cardiac, neural, or nephrotic disease
- Family history of any genetic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Qi-Shield user group
|
New device provides protection against the radiations emitted by the smartphone and laptop devices.
Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
|
Sham Comparator: Sham Qi-Shield user group
|
Sham device as as a control for new device, which provides protection against the radiations emitted by the smartphone and laptop devices.
Device uses conductive fluids in a particular geometric arrangement intended to ameliorate the negative effects of EMW radiation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sperm concentration
Time Frame: 0 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm concentration (millions/ mL) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
0 weeks
|
Sperm concentration
Time Frame: 4 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm concentration (millions/ mL) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
4 weeks
|
Sperm concentration
Time Frame: 8 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm concentration (millions/ mL) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
8 weeks
|
Total sperm motility
Time Frame: 0 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Total motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
0 weeks
|
Total sperm motility
Time Frame: 4 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Total motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
4 weeks
|
Total sperm motility
Time Frame: 8 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Total motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
8 weeks
|
Progressive motility
Time Frame: 0 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Progressive motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
0 weeks
|
Progressive motility
Time Frame: 4 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Progressive motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
4 weeks
|
Progressive motility
Time Frame: 8 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Progressive motility (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
8 weeks
|
Sperm morphology
Time Frame: 0 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm morphology (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
0 weeks
|
Sperm morphology
Time Frame: 4 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm morphology (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
4 weeks
|
Sperm morphology
Time Frame: 8 weeks
|
Semen analysis will be carried out using LensHooke™X1 PRO semen quality analyzer.
Sperm morphology (%) will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group).
|
8 weeks
|
Seminal oxidative stress
Time Frame: 0 weeks
|
ORP is considered as a marker of oxidative stress.
Increased levels of oxidative stress is harmful to the spermatozoa.
In semen samples ORP is measured using MiOXSYS analyzers.
Seminal ORP will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group) to evaluate the change in the seminal oxidative stress due to use of Qi-shield.
|
0 weeks
|
Seminal oxidative stress
Time Frame: 4 weeks
|
ORP is considered as a marker of oxidative stress.
Increased levels of oxidative stress is harmful to the spermatozoa.
In semen samples ORP is measured using MiOXSYS analyzers.
Seminal ORP will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group) to evaluate the change in the seminal oxidative stress due to use of Qi-shield.
|
4 weeks
|
Seminal oxidative stress
Time Frame: 8 weeks
|
ORP is considered as a marker of oxidative stress.
Increased levels of oxidative stress is harmful to the spermatozoa.
In semen samples ORP is measured using MiOXSYS analyzers.
Seminal ORP will be assessed in both the groups (Qi-shield user group and sham Qi-shield user group) to evaluate the change in the seminal oxidative stress due to use of Qi-shield.
|
8 weeks
|
Sperm DNA damage
Time Frame: 0 weeks
|
Sperm DNA integrity is directly correlated with the quality of the spermatozoa.
Increased levels of sperm DNA damage has negative impact on pregnancy and live birth rates.
Sperm DNA fragmentation (SDF) is measured using TUNEL assay.
In the current study levels of SDF before and after the use of Qi-shield will allow us to understand the effect of electromagnetic radiations on DNA integrity of spermatozoa.
|
0 weeks
|
Sperm DNA damage
Time Frame: 4 weeks
|
Sperm DNA integrity is directly correlated with the quality of the spermatozoa.
Increased levels of sperm DNA damage has negative impact on pregnancy and live birth rates.
Sperm DNA fragmentation (SDF) is measured using TUNEL assay.
In the current study levels of SDF before and after the use of Qi-shield will allow us to understand the effect of electromagnetic radiations on DNA integrity of spermatozoa.
|
4 weeks
|
Sperm DNA damage
Time Frame: 8 weeks
|
Sperm DNA integrity is directly correlated with the quality of the spermatozoa.
Increased levels of sperm DNA damage has negative impact on pregnancy and live birth rates.
Sperm DNA fragmentation (SDF) is measured using TUNEL assay.
In the current study levels of SDF before and after the use of Qi-shield will allow us to understand the effect of electromagnetic radiations on DNA integrity of spermatozoa.
|
8 weeks
|
Sperm proteome
Time Frame: 0 weeks
|
In spermatozoa normal expression of fertility associated proteins are essential for fertilization process.
Several studies reported that aberrant expression of proteins related to sperm function as capacitation, hyperactivation, acrosome reaction and binging of zona pellucida with ovum in infertile men.
Furthermore, electromagnetic radiations can also cause molecular changes.
In the present study, proteome profile of the spermatozoa from subjects before and after the use of Qi-shield will provide the information related to the molecular changes at protein level.
|
0 weeks
|
Sperm proteome
Time Frame: 4 weeks
|
In spermatozoa normal expression of fertility associated proteins are essential for fertilization process.
Several studies reported that aberrant expression of proteins related to sperm function as capacitation, hyperactivation, acrosome reaction and binging of zona pellucida with ovum in infertile men.
Furthermore, electromagnetic radiations can also cause molecular changes.
In the present study, proteome profile of the spermatozoa from subjects before and after the use of Qi-shield will provide the information related to the molecular changes at protein level.
|
4 weeks
|
Sperm proteome
Time Frame: 8 weeks
|
In spermatozoa normal expression of fertility associated proteins are essential for fertilization process.
Several studies reported that aberrant expression of proteins related to sperm function as capacitation, hyperactivation, acrosome reaction and binging of zona pellucida with ovum in infertile men.
Furthermore, electromagnetic radiations can also cause molecular changes.
In the present study, proteome profile of the spermatozoa from subjects before and after the use of Qi-shield will provide the information related to the molecular changes at protein level.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ashok Agarwal, PhD, American Center for Reproductive Medicine, Cleveland Clinic
Publications and helpful links
General Publications
- Agarwal A, Deepinder F, Sharma RK, Ranga G, Li J. Effect of cell phone usage on semen analysis in men attending infertility clinic: an observational study. Fertil Steril. 2008 Jan;89(1):124-8. doi: 10.1016/j.fertnstert.2007.01.166. Epub 2007 May 4.
- Agarwal A, Desai NR, Makker K, Varghese A, Mouradi R, Sabanegh E, Sharma R. Effects of radiofrequency electromagnetic waves (RF-EMW) from cellular phones on human ejaculated semen: an in vitro pilot study. Fertil Steril. 2009 Oct;92(4):1318-1325. doi: 10.1016/j.fertnstert.2008.08.022. Epub 2008 Sep 20.
- Agarwal A, Henkel R, Huang CC, Lee MS. Automation of human semen analysis using a novel artificial intelligence optical microscopic technology. Andrologia. 2019 Dec;51(11):e13440. doi: 10.1111/and.13440. Epub 2019 Oct 4.
- Desai NR, Kesari KK, Agarwal A. Pathophysiology of cell phone radiation: oxidative stress and carcinogenesis with focus on male reproductive system. Reprod Biol Endocrinol. 2009 Oct 22;7:114. doi: 10.1186/1477-7827-7-114.
- Kesari KK, Agarwal A, Henkel R. Radiations and male fertility. Reprod Biol Endocrinol. 2018 Dec 9;16(1):118. doi: 10.1186/s12958-018-0431-1.
- Kivrak EG, Yurt KK, Kaplan AA, Alkan I, Altun G. Effects of electromagnetic fields exposure on the antioxidant defense system. J Microsc Ultrastruct. 2017 Oct-Dec;5(4):167-176. doi: 10.1016/j.jmau.2017.07.003. Epub 2017 Aug 2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WAVEGUARD MALE FERTILITY CC01
- IRB #20-329 (Other Identifier: Cleveland Clinic Institutional Review Board)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Infertility
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Reproductive Medicine Associates of New JerseyTerminated
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Hillel Yaffe Medical CenterUnknownMale Infertility With Severe Oligo-terato-asteno-spermiaIsrael
-
Assiut UniversityNot yet recruitingMale Infertility Due to Azoospermia
-
Universitair Ziekenhuis BrusselRecruitingMale InfertilityBelgium
Clinical Trials on sham device against ambient electromagnetic radiation
-
University of British ColumbiaBioElectronics CorporationCompleted
-
Regenesis Biomedical, Inc.CompletedPost-Operative Pain Following Total Knee ArthroplastyUnited States
-
Wake Forest University Health SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingInterstitial Cystitis | Bladder Pain Syndrome | Chronic Interstitial CystitisUnited States
-
Wake Forest University Health SciencesNot yet recruitingInterstitial Cystitis | Bladder Pain Syndrome | Chronic Interstitial CystitisUnited States
-
Paolo CassanoNorth Suffolk Mental Health Association; Mclean HospitalCompletedMajor Depressive DisorderUnited States